Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP ... Prolia, a RANK inhibitor, is one of Amgen’s top-selling drugs with sales of $2.3 billion last year, but will start losing ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's a look under the hood to see if now is a good time to buy, sell ... world's top weight-management drug, but that's not a huge problem for Amgen. In the third quarter, 10 of the company's ...

Amgen (NASDAQ ... Nonetheless, legacy franchises still weighed on top-line results in the most recent quarter. For example, Enbrel, a top-selling autoimmune disease treatment, saw sales drop ...

Central Pacific Bank Trust Division lessened its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 82.3% in the 4th ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.